



MAT
TRAINING

Provided by:



Providers
Clinical Support
System



NORTON
BEHAVIORAL
MEDICINE

Saturday,
Aug. 19, 2023

8 A.M. TO 5:15 P.M.

*Registration and breakfast
begin at 7:30 a.m.*

Norton Healthcare
Learning Center
9500 Ormsby Station Road
Louisville, Kentucky

PROGRAM AGENDA

- 7:30 a.m. **Registration and breakfast**
- 8 a.m. **Overview**
- 8:30 a.m. **Neurobiology**
- 9 a.m. **Patient Evaluation**
- 10 a.m. **Small Group – Case 1: Treatment Options**
- 10:45 a.m. **Break**
- 11 a.m. **Pharmacology**
- 11:45 a.m. **Specialty Topics**
- 12:15 p.m. **Lunch**
- 1 p.m. **Medications for Addiction Treatment (MAT) and Urine Drug Testing**
- 1:45 p.m. **Small Group – Case 2: Addiction and Depression**
- 2:30 p.m. **Evidence-based Counseling**
- 3:10 p.m. **Break**
- 3:25 p.m. **Clinical Management**
- 4 p.m. **Small Group – Case 3: Setting Treatment Goals and Case 4: Cocaine Abuse Program**
- 4:45 p.m. **Questions and answers**
- 5:15 p.m. **Adjournment**

Overview

Medications for opioid use disorder (MOUD) involves a combination of medications that target the brain. Treatment involves a combination of a medication that targets the brain and psychosocial interventions, such as counseling and skills development, aimed at improving treatment outcomes. Research shows that medications and therapy together may be more successful than either treatment method alone.

This program will count toward the new eight-hour training required when applying for or renewing a provider's U.S. Drug Enforcement Administration (DEA) license.

Target audience

This program is intended for physicians, nurse practitioners and physician assistants who provide treatment for opioid use disorder, as well as those interested in learning more about medications for addiction treatment.

Speaker



Kelly Cooper, M.D., MPH, FASAM
Medical Director
Addiction Services
Norton Behavioral Medicine

Educational objectives

1. Screen and identify patients with opioid use disorder (OUD) and define evidence-based treatments.
2. Discuss the pharmacology of opioids as it relates to treatment of OUD patients.
3. Describe the fundamentals of office-based opioid treatment, including the treatment of comorbid patients.
4. Explain the process of buprenorphine induction as well as stabilization and maintenance.
5. Discuss all FDA-approved antagonist and agonist medications to treat OUD.
6. Discuss basic office protocols, including medical record documentation and confidentiality.
7. Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.



Continuing education credits

Physicians

Accreditation: Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians.

Designation: Norton Healthcare designates this live educational activity for a maximum of 8.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

House Bill 1 credits

This program has been approved for 8.0 HB1 credit hours by the Kentucky Board of Medical Licensure, ID #0322-H8.0-NHC1g.

For information related to credits, contact the Norton Healthcare Center for Continuing Medical, Provider & Nursing Education at **(502) 446-5955** or **cme@nortonhealthcare.org**.

Nurses

Kentucky Board of Nursing (KBN) Approved Provider: Norton Healthcare Institute for Education & Development, provider number 4-0002-12-24-076. The program has been approved by Norton Healthcare Institute for Education & Development for 9.6 contact hours, which expires 12/31/2024. KBN approval of a continuing education provider does not constitute endorsement of program content. Nursing participants must attend the entire program, attest to the number of hours of attendance and complete the evaluation to receive contact hours.

This activity meets the required 1.5 contact hours of the dual subjects of pharmacology and pain management continuing education required by the Kentucky Board of Nursing (KBN) for annual license renewal for APRNs with a Collaborative Agreement for Advanced Practice Registered Nurse's Prescriptive Authority for Controlled Substances (CAPA-CS) – 201 KAR 20:215 and an additional 4.0 contact hours of approved addiction disorder continuing education required by the KBN for annual license renewal for APRNs that prescribe buprenorphine to treat opioid use disorders (previously titled DEA-X Waiver/Registration) - 201 KAR 20:065.

For more information related to nursing credits, contact Sally Sturgeon, DNP, R.N., SANE-A, AFN-BC, at **sally.sturgeon@nortonhealthcare.org**.



Registration

There is a registration fee of \$15. For Norton Healthcare employed providers, the fee will be waived. Preregistration is required. Registration is limited.

To register

1. Visit [this link.](#)
2. Scan the QR code:



Location

This program will be held at Norton Healthcare Learning Center located at 9500 Ormsby Station Road in Louisville, Kentucky. The symposium will be held on the second floor in room 1B. Self-parking is available in the lot adjacent to the building.

Program materials

Presentation slides will be available at [NortonCME.com](https://www.nortoncme.com). Select the “Conference Details/Presentation” link and then this activity.

Acknowledgments

Funding for this initiative was made possible in part by grant No. 6H79TI081968 from the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the U.S. Department of Health and Human Services, nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. government.

The American Academy of Addiction Psychiatry (AAAP) is the data sponsor for this training.